PROCEPT BioRobotics Corporation specializes in manufacturing advanced medical and surgical equipment, with a focus on autonomous surgical robots for treating benign prostatic hyperplasia (BPH). Their flagship technology, Aquablation therapy, combines imaging clarity, robotic precision, and water power to offer a novel approach to BPH treatment. This innovative therapy aims to provide effective, safe, and durable outcomes across various prostate sizes and shapes.
The company's Aquablation therapy represents a significant advancement in BPH surgical treatment, addressing the traditional compromise between safety and efficacy. PROCEPT BioRobotics has positioned itself as a pioneer in this field, offering a solution that delivers consistent results regardless of surgeon experience. Their technology has the potential to establish a new standard in BPH treatment, serving patients worldwide.
